Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 5/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9260942 | 0.81 | KIF11 (0.46) | KIF11RXRARXRB | |
| SCHEMBL24721274 | 0.79 | PTPN5 (0.42) | PTPN5KIF11RXRARXRB | |
| SCHEMBL25583367 | 0.79 | AKR1C3 (0.56) | PTPN5KIF11LMNAAKR1C3AKR1C2 | |
| SCHEMBL13524519 | 0.79 | CYP2A6 (0.48) | PTPN5KIF11RXRARXRBLMNA | |
| SCHEMBL22488082 | 0.77 | LMNA (0.53) | LMNAAKR1C3AKR1C2 | |
| SCHEMBL9254405 | 0.77 | AKR1C3 (0.57) | PTPN5KIF11AKR1C3AKR1C2 | |
| SCHEMBL9289288 | 0.76 | PTGS2 (0.47) | PTPN5LMNA | |
| SCHEMBL598661 | 0.74 | KIF11 (0.49) | PTPN5KIF11RXRARXRBLMNA | |
| SCHEMBL18713819 | 0.73 | KIF11 (0.41) | PTPN5KIF11RXRARXRB | |
| SCHEMBL9263214 | 0.72 | KIF11 (0.47) | PTPN5KIF11RXRARXRBAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | PTPN5 1848/4885KIF11 3917/4885RXRA 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.